Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05753501 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
A Phase 1 study of Hematologic Cancer, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 340
- Enrollment target
- 20
- Study locations
NCT05753501 is a Phase 1 study of Hematologic Cancer that is actively recruiting participants, run by AbbVie. The registered enrollment target is 340 participants, above the 179-participant average among 4 other Hematologic Cancer trials with a reported enrollment target (90% higher). The trial reports 20 study locations across 17 states.
The verdict
NCT05753501, a Phase 1 study of Hematologic Cancer, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 340 participants
- Enrollment target
- 20
- Study locations
Study Summary
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult participants in relapsed or refractory (R/R) non-Hodgkin's lymphomas: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large b-cell lymphoma (DLBCL), non-germinal center B cell (GCB) DLBCL, mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), or transformed indolent NHL. Adverse events will be assessed. ABBV-101 is an investigational drug being developed for the treatment of NHL. This study will include a dose escalation phase to determine the maximum administered dose (MAD)/Maximum tolerated dose (MTD) of ABBV-101 and a dose expansion phase to determine the change in disease activity in participants with first line treatment (1L), second line or later of treatment (2L)+ CLL/SLL or third line or later of treatment (3L) non-GCB DLBCL. Approximately 340 adult participants with multiple NHL subtypes will be enrolled in the study in sites world wide. In the Dose Escalation phase of the study participants will receive escalating oral doses of ABBV-101, until the MAD/MTD is determined, as part of the approximately 88 month study duration. In the dose expansion phase of the study participants receive oral ABBV-101, as part of the approximately 88 month study duration . There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.
Conditions Studied
Interventions
- DRUG ABBV-101
Study Locations (20)
New York
- New York Oncology Hematology - Albany Cancer Center /ID# 252240 - Albany
- Northwell Health - Monter Cancer Center /ID# 250422 - Lake Success
- University of Rochester Medical Center /ID# 249324 - Rochester
California
- UC Irvine Medical Center /ID# 263020 - Orange
- Stanford University /ID# 249683 - Palo Alto
Arizona
- Arizona Oncology Associates, PC-HOPE /ID# 252351 - Tempe
Colorado
- Rocky Mountain Cancer Centers - Lone Tree /ID# 252237 - Lone Tree
Illinois
- Northwestern University Feinberg School of Medicine /ID# 249347 - Chicago
Massachusetts
- Beth Israel Deaconess Medical Center /ID# 249302 - Boston
New Jersey
- Rutgers Cancer Institute of New Jersey /ID# 249323 - New Brunswick
Ohio
- UC Health - Cincinnati /ID# 249299 - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2023-06-09 |
| Est. Completion | 2031-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05753501
The ClinicalTrials.gov registry entry for NCT05753501 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 179-participant average among 4 other Hematologic Cancer trials with a reported enrollment target (90% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Cancer appearing as the primary indexed condition, and to 1 intervention - of which ABBV-101 is the first listed.
NCT05753501 reports 20 study locations spanning 17 distinct geographic areas - top geographies include New York, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05753501 about?
NCT05753501 is a clinical study titled "Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies". Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult participants in relapsed or refractory (R/R) non-Hodgkin'...
What is the current status of trial NCT05753501?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 340 participants. The study started on 2023-06-09. Estimated completion is 2031-03.
What conditions does trial NCT05753501 study?
This clinical trial studies the following conditions: Hematologic Cancer.
What interventions are being tested in trial NCT05753501?
The interventions under investigation include: ABBV-101 (DRUG).
Who is sponsoring clinical trial NCT05753501?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05753501 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.